At the start of the COVID-19 pandemic, ICON initiated the CHIEF study, a fully decentralised cardiovascular trial, intending to demonstrate that a drug reduced symptom burden in patients with heart failure at twelve weeks. While COVID-19 presented many challenges, ultimately the decentralised model proved to have clear benefits for patient diversity, retention and compliance. These benefits have since been corroborated by fully decentralised and hybrid trials within the cardiovascular space and other therapeutic areas.
Now, the necessity of rapidly decentralising clinical studies during COVID-19 has been replaced with the intentional development of fully decentralised and hybrid clinical trials, which include elements from both traditional site-based and decentralised clinical trials. Their staying power, post-pandemic, has been further reinforced by the United States’ recent enactment of the Food and Drug Omnibus Reform Act of 2022, which includes provisions intended to improve diversity in trial enrollment through decentralised clinical trials and associated digital health technologies.
We reflect on the success of the first fully decentralised cardiovascular trial implemented at the beginning of the COVID-19 pandemic, and highlight some of the key elements that need to be in place in a decentralised or hybrid setting to realise similar benefits in future trials.
At-home options increase diversity in patient recruitment
Decentralised and hybrid clinical trials overcome two common hurdles for patient recruitment and retention: accessibility and convenience. In our most recent survey in 2021, 90 percent of respondents were not willing to travel more than one hour to participate in a clinical trial. As a result of the physical distance, the burden of travel, and related financial and time investments, site-based trials exclude significant populations. This becomes an especially important factor in long-term cardiovascular trials. Providing decentralised options that improve accessibility and minimise burdens can translate into increased participation from diverse communities.
Besides eliminating travel burdens, the recruitment methods used in decentralised trials can also result in more representative trial populations. Recruiting at the institutional level may eliminate some of the recruitment bias at the investigator level seen in site-based trials. In addition, at-home options can open recruitment eligibility to more rural communities. Together, reduced patient burden and an increased range of eligible patients can result in more representative trial populations.
For the CHIEF study mentioned above, investigators noted greater diversity compared to traditional chronic heart failure trials, which, historically, have under-represented women and lacked racial diversity. Of the patients enrolled, 52 percent were women, and 15 percent were African American, which is reflective of the general US population and higher than prior heart failure trials. In addition, the study enrolled a wide age range of 22 to 91 years, with a median of 64 years.
Other decentralised trials have observed improved inclusivity as well; one North-America based study quickly recruited a representative population (51.6 percent) of female participants from a broader geographical range than is typically seen in site-based trials. In another fully decentralised U.S. study, 25 percent of enrolled participants were black, far more than the standard U.S. recruitment rate of around 4 percent.1
Reducing patient burden with mHealth and wearables
When mobile health (mHealth) and wearable technologies fit seamlessly into patients’ lives, they can support decentralised trial designs and lower trial costs. For instance, many cardiovascular trials require that patients visit sites so that their heart rhythm and or/vital signs can be rechecked – steps that could be unnecessary with wearable technologies that can take biometric data from patients as they go about their daily lives, reducing or eliminating the need for frequent study visits and associated travel.
Digital technologies are proving to be especially useful in cardiovascular trials, because they can capture physiological and real-world data that dovetail perfectly with the signals sought in cardiovascular trials – perhaps more so than in any other therapeutic area. In fact, the digital biosensors available today capture many of the significant endpoints sought in cardiovascular trials. Common mHealth devices include wearable blood pressure monitors, and patches that can produce electrocardiograms – which measure the electrical activity of the heart, and can be used to detect irregular heartbeats. In the CHIEF study, a Fitbit was used to measure accelerometry, a measure of activity that served as the key secondary endpoint. The primary endpoint was based on electronic patient reported outcomes (ePROs) from the Kansas City Cardiomyopathy Questionnaire (KCCQ), which measures patient’s perceived heart failure symptoms and quality of life.
While many companies sponsoring cardiovascular drug trials are interested in using more than one device in a study to measure multiple parameters, that temptation must be balanced with the need to “keep it simple” from the patient’s perspective. Multiple technologies, or a digital technology that is not easy for patients to use can increase patient burdens or reduce compliance, especially in decentralised settings. To support patient centricity, the digital devices must have “maximum passiveness” so that data collection is seamless and unobtrusive. The interface must be simple and convenient to use, and for wearables, the device should also be attractive to wear.
Improving compliance with concierge services
While replacing some, or all, study visits with in-home services can reduce patient burdens related to travel, it can also introduce situations in which patients feel disconnected, ill-prepared or confused. Dedicated concierge services that act as a direct-to-patient contact team are important to ensure patient support is fully embedded in decentralised or hybrid trials.
The expertise to fully support patients in setting up connectivity to digital platforms, devices and wearables should be considered where digital health technologies are included in the clinical trial. And while assisting patients with technical support is essential, ensuring retention requires engagement beyond technical support. Direct inbound and outbound communication with patients improves overall engagement, compliance and retention throughout the trial by onboarding the patient and being a central contact for any challenges they might come up against.
Combining concierge services with remote monitoring and patient engagement apps helps detect compliance issues and allows reminders or other interventions to keep patients on protocol. By increasing touchpoints with trial participants, sponsors can make sure patients are filling out their eDiaries or generating ePROs, for example, on a scheduled basis. They also help to track data from wearables such as electrocardiograms and blood pressure monitors, and can help to resolve any technical problems or human error if data is missing.
In the case of the CHIEF study, concierge services proved to be an effective strategy to engage patients remotely. Following trial enrollment, 98 percent of patients confirmed eligibility, and 0 percent of participants took prohibited medication post-enrollment. Patient compliance was also very high with more than 97 percent ePRO compliant, 95 percent eDiary compliant and 80 percent medication compliant.
Looking to the future of decentralised cardiovascular trials
ICON’s successful delivery of the first fully decentralised cardiovascular study at the beginning of the pandemic has since been replicated many times over, demonstrating that a decentralised or hybrid trial design can improve how clinical studies are conducted, and enhance compliance and diversity. However, a decentralised model does not guarantee benefits to patients. To be successful, in-home services and digital health technologies need to be integrated into the trial design in a way that delivers a seamless trial experience for the patient. With accessible technology, and consistent direct-to-patient contact, cardiovascular patients can receive necessary support, while sponsors gain the benefits of increased patient diversity, retention and compliance.
Explore the successful strategies that ICON deployed in a fully decentralised heart failure study or contact us to speak with our experts about how we can support your cardiovascular clinical trials.
Citations:
Goodson N, Wicks P, Morgan J, Hashem L, Callinan S, Reites J. Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion. npj Digit Med. 2022;5(1):1-6.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel